




RealRate

PHARMACEUTICAL 2022

Acer Therapeutics Inc.
Rank 291 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai

The relative strengths and weaknesses of Acer Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acer Therapeutics Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 29% points. The greatest weakness of Acer Therapeutics Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is -173%, being 103% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	28,089
Cost of Goods Sold	0
Intangible Assets	7,647
Liabilities, Current	29,110
Liabilities, Non-Current	209
Other Assets	407
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	8,661
Other Net Income	574
Property and Equipment	114
Research and Development	6,508
Revenues	1,260
Selling, General and Administrative Expense	10,700

Output Variable	Value in 1000 USD
Assets	36,257
Liabilities	37,981
Expenses	17,208
Stockholders Equity	-1,724
Net Income	-15,374
Comprehensive Net Income	-15,374
Economic Capital Ratio	-173%